European Alpha-Mannosidosis Participant (NCT03651245) | Clinical Trial Compass
TerminatedNot Applicable
European Alpha-Mannosidosis Participant
Stopped: we will update quickly
Germany667 participantsStarted 2018-08-20
Plain-language summary
International, multicenter, observational, longitudinal monitoring study to investigate the prevalence of Alpha-Mannosidosis in participants at risk for Alpha-Mannosidosis.
Who can participate
Age range2 Months – 18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Informed consent is obtained from the participant's parent/legal guardian
* The participant is aged between 2 months and 18 years of age
* The participant has a family history of Alpha-Mannosidosis or is at risk for Alpha-Mannosidosis according to one or more of the following symptoms: recurrent infections, skeletal abnormalities, hearing impairment-deafness, progressive neurological symptoms, impairment of mental functions, gingival hypertrophy, dysmorphic facial features, motoric disturbances of no obvious etiology
Exclusion Criteria:
* Informed consent is not provided by the partici-pant's parent/legal guardian
* The participant is younger than 2 months or older than 18 years
* The participant has no family history of Alpha-Mannosidosis and is not at risk for Alpha-Mannosidosis (represents none of the following symptoms): recurrent infections, skeletal abnormalities, hearing impairment-deafness, progressive neurological symptoms, impairment of mental functions, gingival hypertrophy, dysmorphic facial features, motoric disturbances of no obvious etiology
What they're measuring
1
Epidemiological analysis of the prevalence of Alpha-Mannosidosis disease in a cohort of patients with suspicion for Alpha-Mannosidosis, based on their clinical symptoms.